Abstract:Specific active immunotherapy with DNA vaccines offers the hope for a natural nontoxic alternative to eradicate minimal residual disease in cancer patients. However, little data are regarding the DNA vaccines in leukemia. Our previous study has successfully developed a vector containing PML-RARα segment fused to human Interleukin- 2 (hIL-2) gene. In the present study, we analyzed the specific immune response by immunization with the recombinant plasmid in BALB/c mice. The recombinant plasmids were injected into BALB/C mice with a total of 200 μg DNA in normal saline at 14-day intervals for three cycles. The plasmid containing the same sequence of PML-RARα segment or hIL-2 gene alone and blank plasmid served as controls. Two weeks after the final DNA boost, the transcription and expression of PML-RARα and hIL-2 in injection site were detected by RT-PCR and immunohistological methods; the specific cytotoxicity of spleen cells from the vaccinated BALB/C mice was detected by LDH release assay; interferon-γ secretion was measured by ELISA; antibodies against human PML-RARα were detected by indirect immunofluorescene analysis (flow cytometry); and T-cell receptor rearrangement excision circles (TRECs) in DNA from mice thymic cells were detected by real-time quantitative RT-PCR (TaqMan), thereby to evaluate the content of naïve T cells. After immunization, the PML-RARα/hIL-2 mRNA and protein could be identified in the injection site of PML-RARα- hIL-2 vaccinated mice. Time dependent antibody production and an increase in INF–γ could be detected in vaccinated mice serum (p<0.05). Specific cytotoxicity on NB4 cells was significantly higher than that from control groups (p=0.012). TRECs level form PML-RARα-hIL-2 vaccine group was significantly higher than that from PML-RARα, hIL-2 vaccine or control groups (p<0.05). In conclusions, the reconstructed PML-RARα plasmids might display the common feature of DNA vaccine, which can induce specific humoral and cellular immune responses in BALB/c mice in vivo and can induce the increase of naïve T cells in mice thymus, it might relate to stronger cellular immune response, it is to our knowledge, the first description on the change of naïve T cells in response to vaccine.

[The Experimental Study on the TCR Idiotypic DNA Vaccine to Induce Antitumor Immune Response to Lymphocytic Malignancy]

[Experimental Study on TCRbeta Idiotypic Antigenic Determinants DNA Vaccine to Induce Anti-Lymphoma Antibodies].

The Experimental Study on the Idiotypic Nucleic Acid Vaccine Constructed from the Genomic DNA to Lymphoma

Anti-idiotypic Regulatory Responses Induced by Vaccination with DNA Encoding Murine TCR Valpha5 and Vbeta2.

[Experimental Induction of Immunity by Anti-Idiotypic Vaccines Against Small-Cell-lung Cancer].

Idiotype TCR Vβ2 DNA Plasmid Constructe, Transfer and Express in K562 Cells.

Specific Immune Response Induced by PML-Rarα-hIL-2 Vaccine in BALB/C Mice

Immunization with Autologous T Cells Enhances in Vivo Anti-Tumor Immune Responses Accompanied by Up-Regulation of GADD45β

Study of immunotherapy of murine myeloma by an IL-21-based tumor vaccine in BALB/C mice.

Anti-Tumor Immune Responses in Immune-Reconstituted Mice Injected with A Tumor Vaccine

Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma

Experimental Study of Active Specific Immunotherapy for Cervic Cancer with Tumor Vaccine

Study on the cytotoxic T lymphocytes of mice treated with leukemia vaccine

Vaccination with immature dendritic cells combined with CD40mAb induces protective immunity against B lymphoma in hu-SCID mice.

[Antitumor Immune Responses Induced by Idiotype-Pulsed Dendritic Cells with Cell-Penetrating Peptide Vaccination in Vivo].

A BCR/ABL-hIL-2 DNA vaccine enhances the immune responses in BALB/c mice.

Anti-tumor mechanisms of lymphopenic mice transferred with tumor-specific lymphocytes and immunized with mIL-21 tumor vaccine

Study on the attenuated ConA activated autologous T-cells to enhence the tumor immunity in mice

Study on antitumor effect of minigene DNA vaccine derived from Carcinoembry-onic Antigen ( CEA) gene in mice

Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response

Semi-allogeneic Vaccine for T-cell Lymphoma